retinal vein occlusion (RVO) is classified as either branch (BRVO) or central (CRVO) RVO. The gold standard treatment for macular oedema (MO) secondary to RVO is intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Our study aimed to compare ranibizumab and aflibercept outcomes over a maximum follow-up of five years.
Methods
this retrospective study assessed treatment-naïve RVO patients. Active disease was treated with three loading injections followed by a pro-re-nata (PRN) regimen of an anti-VEGF agent. Visual outcomes and injection frequency were analyzed, with patients stratified according to RVO subtype, anti-VEGF agent used, baseline vision, and age.
Results
316 CRVO-affected eyes and 467 BRVO-affected eyes were analysed. Visual benefits between different treatments did not significantly differ, except in year 1 in ranibizumab-treated BRVO eyes. However, aflibercept-treated CRVO and BRVO eyes required significantly fewer injections during the follow up period. Furthermore, our results confirm that younger patients achieve better visual outcomes with fewer intravitreal injections. Overall, half of our patients did not require further injections after 1 year from diagnosis.
Conclusion
the results demonstrate that anti-VEGF treatment of RVO benefits vision for up to 5 years. Our findings are the first to suggest that compared to ranibizumab, fewer aflibercept injections may be required over five years follow up. Prospective randomised trials are needed to confirm this, alongside further attention to OCT scan features and the effect of patient demographics on treatment outcomes.
AwdehRMElsingSHDeramoVA,et al.Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute visual function questionnaire. Br J Ophthalmol2010; 94: 319–323.
2.
DeramoVACoxTASyedAB,et al.Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute visual function questionnaire. Arch Ophthalmol2003; 121: 1297–1302.
3.
LaouriMChenELoomanM,et al.The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond)2011; 25: 981–988.
4.
KleinRMossSEMeuerSM,et al.The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye study. Arch Ophthalmol2008; 126: 513–518.
5.
PacellaFBongiovanniGMalvasiM, et al.Impact of cardiovascular risk factors on incidence and severity of retinal vein occlusion. Clin Ter2020; 171: e534–e538.
6.
KleinRKleinBEMossSE,et al.The epidemiology of retinal vein occlusion: the Beaver Dam Eye study. Trans Am Ophthalmol Soc2000; 98: 133–141.
7.
RogersSMcIntoshRLCheungN, et al.The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010; 117: 313–319.
JaulimAAhmedBKhanamT,et al.Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina2013; 33: 901–910.
10.
YauJWLeePWongTY,et al.Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J2008; 38: 904–910.
11.
AielloLPAveryRLArriggPG, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med1994; 331: 1480–1487.
12.
AielloLP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res1997; 29: 354–362.
13.
BoydSRZacharyIChakravarthyU, et al.Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol2002; 120: 1644–1650.
14.
NICE. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion, https://www.nice.org.uk/guidance/ta409 (2016, accessed 19 June 2020).
15.
NICE. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion, https://www.nice.org.uk/guidance/ta283 (2013, accessed 19 June 2020).
16.
SivaprasadSAmoakuWHykinP,et al.The Royal College of Ophthalmologists guidelines on retinal vein occlusions: executive summary. Eye (Lond)2015; 29: 1633–1638.
17.
LiewGLeeAYZarranz-VenturaJ, et al.The UK Neovascular AMD database report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye (Lond)2016; 30: 1462–1468.
18.
CorazzaPKabbaniJSoomroT,et al.Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization. Eur J Ophthalmol2020; 2: 1120672120963455.
19.
LeeAYLeeCSButtT, et al.UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol2015; 99: 1045–1050.
20.
CorazzaPD’AlterioFMKabbaniJ, et al.Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. BMC Ophthalmol2021; 21: 300.
21.
LightJGTianJWenickAS. Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy: prognosis and predictive factors. Ophthalmol Retina2021; 5: 888–900.
22.
BrownDMHeierJSClarkWL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol2013; 155: 429–437; e7.
23.
KorobelnikJFHolzFGRoiderJ, et al.Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology2014; 121: 202–208.
24.
CampochiaroPAHeierJSFeinerL, et al.Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010; 117: 1102–1112.
25.
BrownDMCampochiaroPASinghRP, et al.Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010; 117: 1124–1133.
26.
CampochiaroPAClarkWLBoyerDS, et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015; 122: 538–544.
27.
WuLAconDBerrocalMH, et al.Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: results of the Pan-American collaborative retina study (PACORES) group. Int Ophthalmol2021; doi: 10.1007/s10792-021-02077-5. Epub ahead of print.
28.
HoggHJDi SimplicioSPearceMS. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion. Eur J Ophthalmol2021; 31: 548–555.
29.
CostaJVMoura-CoelhoNAbreuAC,et al.Macular edema secondary to retinal vein occlusion in a real-life setting: a multicenter, nationwide, 3–year follow-up study. Graefes Arch Clin Exp Ophthalmol2021; 259: 343–350.
30.
HykinPPrevostATVasconcelosJC, et al.Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol2019; 137: 1256–1264.
31.
SpoonerKFraser-BellSHongT,et al.Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ Open Ophthalmol2019; 4: e000249.
32.
SpoonerKLFraser-BellSHongT,et al.Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye (Lond)2021; doi: 10.1038/s41433-021-01620-z. Epub ahead of print.
33.
ScottIUVanveldhuisenPCIpMS. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA2017; 317: 2072–2087.
34.
Battaglia ParodiMRomanoFArrigoA,et al.Ranibizumab for macular edema secondary to central and branch retinal vein occlusion in patients younger than 50 years of age. Biomed Res Int2020; 2020: 4747696.
35.
DewanKSHentatiFGreenleeTE,et al.Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion. Can J Ophthalmol2021; 56: 96–104.
36.
OguraYRoiderJKorobelnikJF, et al.Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol2014; 158: 1032–1038.
37.
Schmidt-ErfurthUGarcia-ArumiJGerendasBS, et al.Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica2019; 242: 123–162.
38.
CiullaTPollackJSWilliamsDF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol2021; 105:1696-1704.
39.
SenPGurudasSRamuJ,et al.Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion. Ophthalmol Retina2021; 5: 1115–1124.
